There remains a need to create a host active specific immune response, generating an army of tumor reactive T-cells that can attack a patient’s disease alone and improve the outcomes for patients on therapies that manipulate T cells in the adjuvant and metastatic settings.
TLPLDC is an autologous therapeutic cancer vaccine that is made from a patient’s own cells and is designed to stimulate the immune system to recognize tumor cells and fight the patient's specific (or unique) cancer.